Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Skin & Joints: Experts Discuss Advances in PsA

Thomas R. Collins  |  November 25, 2023

SAN DIEGO—The understanding of the microenvironment in which immune cells interact with stromal cells in the synovium of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) is deepening, potentially giving clues for treatments. As this understanding improves, so does the appreciation for its astounding complexity, an expert said here in a session at ACR Convergence, which also included discussions on the microbiome in PsA and a new mouse model for PsA.

Mechanisms 

Ursula Fearon, PhD

Ursula Fearon, PhD, professor of molecular rheumatology at Trinity College Dublin, said that while common mechanisms of disease are at play in both RA and PsA, they differ in many aspects due to the complex microenvironment of the joint, including the presence or absence of autoantibodies, distinct vascular morphology and different cellular infiltrates, such as macrophages, T cells and B cells.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Even she finds the complexity staggering. When her lab did a single-cell analysis on the whole synovium two years ago, the researchers found 33 subclusters of cell types in the RA and PsA joint, and since then that number has increased to about 50.

“I’m just showing you this to [illustrate] how complex the microenvironment of the joint is,” she said. “And I’m amazed sometimes that we even have one therapy that works in any of these diseases.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In images of healthy joints, RA joints and PsA joints, stark differences can be seen: the translucent synovium of the healthy joint, with just a few blood vessels nourishing it; the increased synovitis in the RA and PsA joint, with distinct vascular morphology demonstrated with straight, regular, branching blood vessel observed in RA in comparison to the dilated, elongated, tortuous blood vessels seen in PsA.

What accounts for these differences?

Through an extensive series of analyses of single cells and flow cytometry, her lab has found distinct differences in the characteristics of fibroblasts in RA joints and PsA joints. The fibroblasts dominant in PsA are associated with invasion and extracellular matrix regulation, while in RA, the dominant fibroblasts are associated with immune-cell regulation and cytoskeletal rearrangement.

When they looked at macrophages in RA and PsA, the researchers didn’t find distinct M1-like macrophages, associated with an inflammatory environment, or M2-like macrophages, associated with an anti-inflammatory environment. Instead, they found that an anti-inflammatory, an M2-like macrophage was dominant, but highly expressed a pro-inflammatory marker, CD40, which was expressed at higher levels in RA than in PsA and minimally expressed in HC, according to Dr. Fearon.1

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2023ACR Convergence 2023 PsAPsA Resource Center

Related Articles

    The Heterogeneity of Psoriatic Arthritis

    November 21, 2023

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Looking to Psoriatic Arthritis History to Disrupt Current Thinking

    May 4, 2022

    As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEFor 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints…

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    September 20, 2018

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences